

**Anti-TNFRSF7 / CD27 Reference Antibody (varlilumab)  
Recombinant Antibody  
Catalog # APR10089****Specification****Anti-TNFRSF7 / CD27 Reference Antibody (varlilumab) - Product Information**

Application	FC, Kinetics, Animal Model
Primary Accession	<a href="#">P26842</a>
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	145 KDa

**Anti-TNFRSF7 / CD27 Reference Antibody (varlilumab) - Additional Information****Target/Specificity**  
TNFRSF7 / CD27**Endotoxin**  
< 0.001EU/ µg,determined by LAL method.**Conjugation**  
Unconjugated**Expression system**  
CHO Cell**Format**  
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.**Anti-TNFRSF7 / CD27 Reference Antibody (varlilumab) - Protein Information****Name** CD27 ([HGNC:11922](#))**Function**  
Costimulatory immune-checkpoint receptor expressed at the surface of T-cells, NK-cells and B-cells which binds to and is activated by its ligand CD70/CD27L expressed by B-cells (PubMed:<a href="http://www.uniprot.org/citations/28011863" target="\_blank">28011863</a>). The CD70-CD27 signaling pathway mediates antigen- specific T-cell activation and expansion which in turn provides immune surveillance of B-cells (PubMed:<a href="http://www.uniprot.org/citations/28011863" target="\_blank">28011863</a>). Mechanistically, CD70 ligation activates the TRAF2-PTPN6 axis that subsequently inhibits LCK phosphorylation to promote phenotypic and transcriptional adaptations of T-cell memory (PubMed:<a href="http://www.uniprot.org/citations/38354704" target="\_blank">38354704</a>). In addition, activation by CD70 on early progenitor cells provides a negative feedback signal to leukocyte differentiation during immune activation and thus modulates hematopoiesis (By similarity). Negatively regulates the function of Th2 lymphocytes in the adipose tissue (By

similarity).

#### Cellular Location

Cell membrane; Single-pass type I membrane protein

#### Tissue Location


Found in most T-lymphocytes.

### Anti-TNFRSF7 / CD27 Reference Antibody (varlilumab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


### Anti-TNFRSF7 / CD27 Reference Antibody (varlilumab) - Images




Anti-TNFRSF7 / CD27 Reference Antibody (varlilumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-TNFRSF7 / CD27 Reference Antibody (varlilumab) is more than 100%, determined by SEC-HPLC.



Immobilized human CD27 FC at 2 µg/mL can bind Anti-TNFRSF7 / CD27 Reference Antibody (varlilumab)  $EC_{50}=0.01912$  µg/mL



HumanCD27 HEK293 cells were stained with Anti-TNFRSF7 / CD27 Reference Antibody (varlilumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS,  $EC_{142}=0.095$  ug/mL